CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical […]